Kornimate/medical-research-clean huggingface dataset:
ulcer monitoring in diabetes mellitus

Conditions: Diabetes Mellitus; Foot Ulcers

Summary: telemedicine technology enables a direct and online text- and image communication in the treatment system from patient to the ulcer specialist. the technology is expected to have patient-related, economic and therapeutic benefits. the study is a substudy of a larger project entitled "renewing health", where also the economic and management aspects are highlighted. however, only few randomized prospective studies are conducted in this field. the purpose of the study is in a randomized prospective study, to assess the impact of the introduction of the telemedicine technology as consultation form between ulcer-nurses in the primary sector and the wound clinics at the hospitals in the region. it is assessed whether the technology can be adopted without incurring the patient a risk. the study aims to perform an impact analysis of the introduction of new technologies for telemedicine wound monitoring in the treatment of diabetic foot ulcers through different studies.

through randomized and prospective studies the project will show whether a telemedicine approach to wound care can be used as an alternative to traditional attendance at a wound clinic and document whether this consultation form provides a greater patient-satisfaction and cost savings. the project will document that telemedicine is equivalent to conventional outpatient attendance from a therapeutic aspect in terms of number of hospitalizations, number of extra controls, acute interventions and wound healing. the project is also investigating the extent of time spent on the personnel side using telemedicine consultations compared with conventional outpatient appearances.

Eligibility criteria:
inclusion criteria: * having diabetic foot ulcer * referred for out-patient clinic treatment by general practitioner * referred for out-patient clinic treatment by a surgical department * living in region of southern denmark exclusion criteria: * psychiatric disorder * dementia * chronic alcohol abuse which can affect compliance * other disorder then diabetes mellitus that have caused foot ulcer (rheumatoid arthritis or arthritis urica) * serious kidney disease which requires dialysis * previous foot ulcer - which was part of the study * expected healing within 2-4 weeks where only one control (final) is expected

Keywords: diabetic foot ulcer ulcer monitoring telemedicine consultations cross-sectoral collaboration
continuous glucose monitoring system (cgms) in type 2 diabetic patients inadequately controlled by metformine monotherapy; analyze of glycemic profile before and after association of glimepiride

Conditions: Diabetes Mellitus

Summary: analyse the glucose profile, based on continuous glucose monitoring by cgms, in type 2 diabetics inadequately controlled by metformin, before and after the addition of glimepiride.


Eligibility criteria:
inclusion criteria: * men or women aged 35 to 70 years * having given their consent * type 2 diabetics (hba1c greater than 6.5% * fasting glycaemia greater than 1.40 g/l) not controlled by metformin for at least 6 weeks.
treatment of neutropenic patients with fever who are suspected to have a gram positive infection

Conditions: Febrile Neutropenia

Summary: this study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).


Eligibility criteria:
inclusion criteria: patients must have neutropenia (anc less than 500) with fever (oral temp 38.3 c). patients must have a cancer with recent chemotherapy and risks factors for gram positive infections. exclusion criteria: patients with fever due to known causes. patients with hiv. patients with recent bone marrow transplant. patients with an infected indwelling catheter that cannot be removed. patients who have received more than one day of another antibiotic before entering the trial. patients with endocarditis, osteomyelitis, meningitis, cns infections.
ankle assistance and resistance in older adults

Conditions: Sarcopenia

Summary: the goal of this research protocol is to improve mobility in older individuals through advances in wearable assistive devices by focusing on two specific aims. the first aim is to study if targeted ankle resistance gait training improves walking performance in older individuals. the second aim is to evaluate the potential of wearable assistance at the ankle, knee, and/or hip joints to increase walking performance in older individuals.

the overarching goal of this study is to improve mobility in older adults through advances in wearable assistance (i.e. powered orthoses). this goal will be accomplished by focusing on two specific research aims. the first aim is to study if targeted ankle resistance gait training improves walking performance in older individuals. the second aim is to evaluate the potential of wearable assistance at the ankle, knee, and/or hip joints to increase walking performance in older individuals. several powered orthosis conditions will be tested during several modes of walking or running and balance throughout the course of the study. trials will take place over-ground and/or on a treadmill. balance trials will take place on a treadmill. participants will walk for up to 40 minutes. frequent breaks will be provided between trials and conditions to avoid fatigue; a maximum of 15 minutes of continuous walking will take place between breaks.

Eligibility criteria:
inclusion criteria: * age between 65 and 85 years old, inclusive. * must be able to understand and follow simple directions based on parent report and clinical observation during the history and physical examination. * able to provide verbal assent, if appropriate. if the participant is non-verbal, parental interpretation of gesticulation for assent will be used. * the ability to read and understand english. * able to walk at least 30 feet with or without a walking aid * able to safely fit into a device configuration and tolerate assistance without knee hyperextension while walking exclusion criteria: * any neurological, musculoskeletal or cardiorespiratory injury, health condition ( including pregnancy), or diagnosis that would affect the ability to walk as directed for short periods of time. note: for elderly participants, a history of joint replacement or joint degeneration that does not impair their ability to walk safely is allowable. * participant or parent report that the perspective participant's physician has recommended that they not engage in moderate intensity walking exercise.
proflaxis using hydroxychloroquine plus vitamins-zinc during covid-19 pandemia

Conditions: Pneumonitis; Coronavirus Infection

Summary: healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminc including zinc once a day were included in the study. study has conducted on 20th of march. main purpose of the study was to cover participants those who are facing or treating covid19 infected patients in ankara.

healthcare professionals mainly doctors, nurses and their first degree relatives (spouse, father, mother, sister, brother, child) who have been started hydroxychloroquine(plaquenil) 200mg single dose repeated every three weeks plus vitaminc including zinc once a day were included in the study. study has conducted on 20th of march. main purpose of the study was to cover participants those who are facing or treating covid19 infected patients.participants, age, sex, bmi, smoking history, comorbid disease were also registered.

Eligibility criteria:
inclusion criteria: 1. person who are working as health professional with contact to known covid positive case 2. their first degree relatives (child, spouse or parents) 3. must be able to swallow tablets exclusion criteria: 1. already using plaquenil for other reasons (ra etc) 2. person with the diagnosis of covid infection 3. person with the condition may cause complications with this medication (severe cvd, av block, already has ophtalmological complications, organ failure of any degree etc). 4. documented allergic history to chloroquine; 5. documented history of hematological system diseases; 6. documented history of chronic liver and kidney diseases; 7. documented history of cardiac arrhythmia or chronic heart diseases; 8. documented history of retina or hearing dysfunction; 9. documented history of mental illnesses; 10. use of digitalis due to the previous disease.

Keywords: hydroxychloroquine coronavirus prophylaxis healthcare professional outbreak
transcranial direct current stimulation combined with oral feeding on dysphagia

Conditions: Stroke

Summary: the study is a double-blind randomized controlled trial, lasting for 15 days for each participant. patients with post-stroke dysphagia who receive treatment at the rehabilitation department are selected as the study subjects. the patients are randomly assigned to either the experimental group or the placebo group. all patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using intermittent oro-esophageal tube. in addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.

transcranial direct current stimulation is currently very popular. the study is a double-blind randomized controlled trial, lasting for 15 days for each participant. patients with post-stroke dysphagia who receive treatment at the rehabilitation department are selected as the study subjects. the patients are randomly assigned to either the experimental group or the placebo group. all patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using intermittent oro-esophageal tube. in addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for ischemic stroke; * age \> 18 years; * first-time stroke; * swallowing disorder confirmed by swallowing contrast study or flexible endoscopic evaluation of swallowing; * requires enteral nutrition support; * stable vital signs, no severe cognitive impairment or aphasia, able to cooperate with treatment; * transferred to the rehabilitation department within fifteen days of onset; stable vital signs. exclusion criteria: * presence of contraindications for invasive oral endoscopy; * concurrent presence of other neurodegenerative diseases that may cause swallowing disorders, such as neurodegenerative diseases; * concurrent presence of other neurological disorders; * tracheostomized patients; * concurrent liver, kidney failure, tumor, or hematological disorders; * pregnancy; * presence of contraindications for transcranial direct current stimulation, such as epilepsy, cerebral edema; * recent use of centrally acting drugs that interfere with the effects of transcranial direct current stimulation, such as carbamazepine, phenytoin, valproic acid, etc.
transcranial direct current stimulation and autism

Conditions: Autism Spectrum Disorders

Summary: this research is being done to determine whether transcranial direct current stimulation (tdcs) can improve certain mental abilities, such as speech, language and other efforts at communication in individuals with autism. in this research, battery powered device is used to deliver very weak electrical current to the surface of the scalp while participants are involved in tasks aimed at training or measuring communicative efforts, speech, language or related cognitive functions. our aim is to find out whether tdcs will improve these mental abilities.

participants in the study will be asked to do the following things: * grant permission for the researchers to view medical/psychological and/or educational and/or speech records associated with the diagnosis of low-functioning autism. * complete a questionnaire and provide a health history. * complete evaluations by our study team to assess the diagnosis and gain a clearer understanding of the participant's current functioning. * give permission to audio and video-tape test sessions for later scoring and observation. * give permission to audio or video-tape in the classroom or home environment using non-intrusive audio-visual recording devices. * complete several tasks and training interventions that involve such things as learning new words or pictures, saying words out loud, or naming objects. * participate in an eye tracking study while completing a task on the computer which involves wearing a headband, attached by a velcro fastener, which contains a magnetic sensor. this equipment allows us to track the position of the head in order to record more accurate measurements. it is used with eye tracking equipment which measures the gaze on a set point on a computer screen. the equipment poses no risk and is non-invasive. * participate in computerized tasks while monitoring brain responses that are a direct result of a thought or perception. in order to monitor these responses, electrodes would be placed over various points on your scalp. the electrodes will record the on-going activity of the brain; it does not produce or introduce any electrical activity. the equipment poses no risk and is non-invasive. * wear electrodes that will be placed on the scalp with a large rubberized band. these electrodes will administer very weak electrical current (tdcs) from a battery powered device for 20 to 60 minutes. the experimental sessions will last about 1 hour and participants may be asked to have more than one testing session in a day or to return for additional sessions.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of autism or related conditions * identified language deficit(s) and/or other cognitive or behavioral impairments (which will be specific to each sub-study) * adequate ability to perform the research tasks set for the individual's particular level of performance exclusion criteria: * peripheral blindness or deafness * any implanted metal device (precludes use of tdcs) * any implanted cardiac pacemaker

Keywords: autism tdcs
the vangas-trial. the value of neurofilament light chain and glial fibrillary acid protein in the blood of patients with asymptomatic carotid artery stenosis

Conditions: Carotid Artery Stenosis; Carotid Artery Stenosis Asymptomatic; Carotid Artery Diseases; Carotid Artery Plaque

Summary: stroke is the second leading cause of death and the third leading cause of disability worldwide. the cause is usually either a blockage or a severe narrowing of a cerebral artery. an important part of stroke prevention is the diagnosis and clarification of stenosis in the arteries supplying the brain, both inside and outside the skull, in order to diagnose a high-grade stenosis at an early stage and offer the patient revascularization. in particular, asymptomatic carotid artery stenosis confronts the diagnosing physician with the question of whether revascularisation is necessary. risk factors for stroke in asymptomatic carotid artery stenosis include contralateral tia or cerebral infarction, male gender, rapid progression of the degree of stenosis, plaque morphology, clinically silent cerebral infarctions, doppler sonographic evidence of microemboli or reduced vasomotor reserve. an established biomarker does not exist at this time. a candidate for such a biomarker in the blood is the protein \&#34;neurofilament light chain\&#34; (nfl), which is already established in the diagnosis of dementia. as a component of the cytoskeleton of neurons, it is released into the patient\&#39;s blood when the cells are damaged and can be measured there. another candidate is glial fibrillary acid protein (gfap), a part of the cytoskeleton of glial cells that is also released into the blood when glial cells are damaged. a systematic investigation of the value of neurofilament light chain and the glial fibrillary acidic protein in the blood of patients with asymptomatic carotid stenosis is still lacking. vangas determines the value of nfl and gfap from the blood of patients with asymptomatic carotid stenosis to determine associations with the degree of stenosis, the natural course of the stenosis (increase or decrease) and possible symptoms of the stenosis as well as the functional outcome after symptomatic stenosis.


Eligibility criteria:
inclusion criteria: * age 60- 80 years * 0-100 % stenosis of the internal carotid artery exclusion criteria: * neurodegenerative diseases such as any form of dementia or parkinson\&#39;s disease * polyneuropathy * multiple sclerosis * stroke (ischaemic or haemorrhagic) within the last 12 months * transient ischaemic attack within the last 12 months * neurotrauma within the last 12 months * atrial fibrillation

Keywords: carotid artery stenosis carotid artery plaque carotid artery disease carotid artery stenosis asymptomatic carotid artery stenosis biomarker carotid artery nfl carotid artery gfap carotid artery plaque biomarker
prediction of getting peripheral neuropathy in patients treated with bortezomib?

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: investigation of which patients treated with bortezomib that have increased risk of developing peripheral neuropathy.

the study aims to include 20 patients with multiple myeloma that are initiating bortezomib treatment. the patients must follow their normal treatment cycles while getting blood drawn during their treatment period however maximal 9 cycles. blood is dawn before treatment initiation and approximately once per cycle in order to measure neurofilament light chain (nfl) before and during treatment. the primary outcome is to relate the level of nfl during treatment with the level at baseline and as a secondary outcome to relate the level of nfl to the cumulative dose of bortezomib.

Eligibility criteria:
inclusion criteria: * above 18 years of age * must speak and understand danish * must be able to and willing to give informed consent * diagnosed with myeloma and in need for treatment * must not be a candidate for transplantation and must be a candidate for bortezomib treatment. * must not previously have been treated with proteasome inhibitors * eastern cooperative oncology group (ecog) performance status (ps) ≤ 3 exclusion criteria: * other underlying cancer disease - with exception of a) basal cell carcinoma, b) healed carcinoma in situ cervicis uteri, c) other cancer disease with minimal risk of recurrence or d) prostate cancer with low glean score * previous treatment with neurotoxic chemotherapy * known polyneuropathy or at diagnosis have polyneuropathy degree 1 with pain or degree 2 without pain. * simultaneous amyloidosis/poems syndrome * patients who have received chemotherapy previously and patients with diabetes, hiv and neurodegenerative diseases.

Keywords: neurofilament light chain nfl proteasome inhibitor chemotherapy-induced peripheral neuropathy
comparing maintenance of device mastery with turbohaler© vs. spiromax© in healthcare professionals naïve to both devices

Conditions: Asthma

Summary: this study is conducted to assess the ease of device mastery of a placebo symbicort turbohaler vs a placebo budesonide/formoterol spiromax device among healthcare professionals in-training (hcp).

the purpose of this study is to identify how intuitive devices are to use and what level of training is required to ensure that hcps are able to demonstrate the correct technique. the two devices examined will be the symbicort turbohaler and placebo budesonide/formoterol spiromax device among healthcare professionals (hcp).

Eligibility criteria:
inclusion criteria: * written informed consent is obtained and dated by the participant before conducting any study related procedures. * the participant is a student that is currently enrolled in the university where the study is conducted * the participant must be willing and able to comply with study restrictions and to remain at the study site for the required duration during the study period, and willing to return to the site for the follow up evaluation as specified in this protocol. * the participant has not previously used or received training in the use of either the spiromax or the turbohaler in the last 6 months exclusion criteria: * participants will be excluded from participating in this study if they have asthma.
effectiveness of animation-based education given to elderly patients undergoing coronary artery bypass graft surgery

Conditions: Surgery

Summary: it was conducted to measure the effectiveness of animation-based training given to elderly patients who will undergo coronary artery bypass graft surgery on the patients' pain, fear, anxiety and self-care management. the study will be completed with 72 participants, 35 experimental and 37 control. as a randomization method, simple randomization method will be used to ensure equal number of samples in the two groups, and patients will be verbally informed about the study and written informed consent will be obtained from the patients who agree. in this study, the effectiveness of animation-based training given to elderly patients undergoing coronary artery bypass graft surgery on pain, fear, anxiety and self-care management will be evaluated.

experimental: patients in the experimental group will be given animation-based video training with a laptop one day before the surgery. the animation-based video training lasts 8 minutes and 35 seconds in total. patient information form, self-care management in chronic diseases scale, visual analog scale, hospital anxiety depression scale, surgical fear scale (turkish version) will be applied. control: in the preoperative period, no training will be given by the researcher to the patients constituting the control group. patients in this group will receive the routine training of the clinic before surgery. patient information form, self-care management in chronic diseases scale, visual analog scale, hospital anxiety depression scale, surgical fear scale (turkish version) will be applied.

Eligibility criteria:
inclusion criteria: * 65 years of age or older, * no diagnosed functional disability, * first scheduled coronary artery bypass graft surgery, * those who volunteered to participate in the study exclusion criteria: * urgent cases, * cases with additional surgical procedures

Keywords: nursing elderly patient anxiety self-care management pain fear coronary artery bypass surgery